Bionest has a very long history of assessing the commercial prospects for new medical products. Our strong scientific background provides the skills to gain a deep understanding of innovative products, in a multiplicity of therapeutic fields, which we then combine with strong forecasting methodology. Our approach begins with in-depth qualitative interviews with Key Opinion Leaders in the relevant field. After defining the product’s value proposition we test our findings with a combination of payers, competitors and industry executives before constructing detailed financial models using probabilistic forecasting. Our forecasts are often used to guide clinical development decisions.
Opportunity assessments also underpin our Strategy Development, New Product Planning and European Market Entry assignments.